Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07462767 · ClinicalTrials.gov registry record · Phase 1
Precision Microbiota Interventions for Senoreduction Trial
A Phase 1 study, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- Not yet
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
NCT07462767: Clinical Trial Phase 1 study, sponsored by Louisiana State University Health Sciences Center in New Orleans.
NCT07462767 is a Phase 1 study that has not yet begun recruiting, run by Louisiana State University Health Sciences Center in New Orleans. The registered enrollment target is 160 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (167% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07462767, a Phase 1 study, has not yet begun recruiting, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
Study Summary
People with HIV who drink alcohol are at increased risk for accelerated aging biology, including increased immune senescence. This randomized, double-blind, crossover clinical trial evaluates two generally recognized as safe (GRAS) microbiota-targeted interventions on immune senescence biomarkers.
Primary Outcome
Change in circulating CD3+CD8+CD28-CD38+ T cell count (cells/µL) during treatment period. Measured by multiparameter flow cytometry. The primary endpoint is the within-participant difference in change from baseline.
Interventions
- DIETARY_SUPPLEMENT Limosilactobacillus reuteri
- DIETARY_SUPPLEMENT Blueberry extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2029-12-01 |
| Phase | Phase 1 |
What is known before NCT07462767 opens enrollment
NCT07462767 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (167% higher).
The record links to 0 conditions, and to 2 interventions - of which Limosilactobacillus reuteri is the first listed.
NCT07462767 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07462767 about?
NCT07462767 is a clinical study titled "Precision Microbiota Interventions for Senoreduction Trial". People with HIV who drink alcohol are at increased risk for accelerated aging biology, including increased immune senescence. This randomized, double-blind, crossover clinical trial evaluates two generally recognized as safe (GRAS) microbiota-targeted interventions on immune senescence biomarkers.
What is the current status of trial NCT07462767?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2026-04-01. Estimated completion is 2029-12-01.
What interventions are being tested in trial NCT07462767?
The interventions under investigation include: Limosilactobacillus reuteri (DIETARY_SUPPLEMENT), Blueberry extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07462767?
This trial is sponsored by Louisiana State University Health Sciences Center in New Orleans, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07462767's enrollment target sits among peer trials
160 340th of 2000 higher than 1,655 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI